Related Experiment Video
Updated: Jun 7, 2025
08:41
Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
2.7K
SARS-CoV-2 Resistance to Small Molecule Inhibitors
Uxua Modrego Lopez1, Md Mehedi Hasan1, Brandon Havranek2
1Department of Chemistry, Delaware State University, Dover, DE 19901, USA.
Current Clinical Microbiology Reports
|November 19, 2024
Summary
SARS-CoV-2 mutations can create drug-resistant variants. This review examines mutations in 3CLpro and nsp12, crucial for antiviral drug efficacy, and discusses new small molecule antivirals.
Area of Science:
- Virology
- Drug Discovery
- Genetics
Background:
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is prone to genetic mutations.
- Emerging variants can exhibit altered transmissibility, disease severity, and drug susceptibility.
- Understanding viral evolution is key to managing the pandemic and developing effective treatments.
Purpose of the Study:
- To review mutations in SARS-CoV-2 3CLpro and nsp12 that may impact antiviral drug efficacy.
- To summarize recent advancements in small molecule antivirals targeting SARS-CoV-2.
- To assess the potential for antiviral resistance in emerging SARS-CoV-2 variants.
Main Methods:
- Literature review of scientific publications.
- Analysis of genetic mutation data in SARS-CoV-2.
- Review of clinical and preclinical data on antiviral drug effectiveness.
Main Results:
- Specific mutations in 3CLpro and nsp12 have been identified that could confer resistance to existing antiviral therapies.
- Nirmatrelvir, Ensitrelvir, Remdesivir, Favipiravir, and Molnupiravir target 3CLpro or nsp12.
- Emerging SARS-CoV-2 variants may possess mutations that reduce the effectiveness of current small molecule antivirals.
Conclusions:
- Mutations in key viral targets like 3CLpro and nsp12 pose a significant threat to the efficacy of SARS-CoV-2 antiviral drugs.
- Continuous monitoring of viral mutations and ongoing research into novel antiviral agents are essential.
- Development of next-generation antivirals should consider potential resistance mechanisms driven by viral evolution.
